As of November 6, 2026, Corbus Pharmaceuticals Holdings, Inc. is a publicly traded company (Nasdaq: CRBP); its largest reported holder is RA Capital, with 9.9% on Schedule 13G of September 30, 2026, then Cormorant Asset Management, LP (7.76%) (Schedule 13G, September 30, 2026).
Is this your company?
About to sign with, pay or invest in Corbus Pharmaceuticals Holdings, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Corbus Pharmaceuticals Holdings, Inc. a real, registered company?
- Corbus Pharmaceuticals Holdings, Inc. files with the SEC under CIK 1595097 (its SEC filings).
- Its shares are listed under the ticker CRBP on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Norwood, Massachusetts, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Corbus Pharmaceuticals Holdings, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Brent Pfeiffenberger, Director (Form 8-K filed 2026-05-14). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Cormorant Asset Management, LP (filed 2026-11-02).
Who are Corbus Pharmaceuticals Holdings, Inc.'s owners and officers?
Corbus Pharmaceuticals Holdings, Inc.: incorporated in Delaware; business address in Norwood, Massachusetts; industry Pharmaceutical Preparations (Schedule 13G/A, 2026-11-02).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-02 | Cormorant Asset Management, LP | 7.76% |
| Schedule 13G/A, 2026-10-29 | Aberdeen Group PLC | 0% |
| Schedule 13G, 2026-09-30 | Ra Capital Management, L.P. | 9.9% |
| Schedule 13G/A, 2026-08-14 | Citadel Securities LLC | 1.1% |
| Schedule 13G, 2026-07-27 | Blackrock, Inc. | 5.9% |
| Schedule 13G/A, 2026-05-14 | Octagon Capital Advisors LP | 0% |
| Schedule 13G/A, 2026-02-10 | Octagon Capital Advisors LP | 5.4% |
| Schedule 13G, 2026-01-16 | Aberdeen Group PLC | 7.53% |
| Schedule 13G/A, 2025-12-15 | Cormorant Asset Management, LP | 13.36% |
| Schedule 13G/A, 2025-11-14 | Cormorant Asset Management, LP | 12.82% |
| Schedule 13G, 2025-11-12 | Kenneth Griffin | 5.3% |
| Schedule 13G/A, 2025-07-29 | The Vanguard Group | 4.89% |
Questions about who owns Corbus Pharmaceuticals Holdings, Inc.
Who owns Corbus Pharmaceuticals Holdings, Inc.?
On this page, 4 holders' latest ownership filings report 5% or more of Corbus Pharmaceuticals Holdings, Inc.: Ra Capital Management, L.P. (9.9%, Schedule 13G, filed 2026-09-30), Cormorant Asset Management, LP (7.76%, Schedule 13G/A, filed 2026-11-02), Blackrock, Inc. (5.9%, Schedule 13G, filed 2026-07-27) and Kenneth Griffin (5.3%, Schedule 13G, filed 2025-11-12).
Who are the largest shareholders of Corbus Pharmaceuticals Holdings, Inc.?
By the share each holder's latest filing reports, the largest holders of Corbus Pharmaceuticals Holdings, Inc. on this page are Ra Capital Management, L.P. (9.9%), Cormorant Asset Management, LP (7.76%) and Blackrock, Inc. (5.9%).
When did Ra Capital Management, L.P. buy into Corbus Pharmaceuticals Holdings, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Ra Capital Management, L.P. on this page is the Schedule 13G, filed 2026-09-30, reporting 9.9%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Corbus Pharmaceuticals Holdings, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Corbus Pharmaceuticals Holdings, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Corbus Pharmaceuticals Holdings, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-05-14 | Brent Pfeiffenberger | Director | appointed |
Which insiders own Corbus Pharmaceuticals Holdings, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- Bihua Chen: 1,919,971 shares (9.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-02).
- Cormorant Asset Management, LP: 1,919,971 shares (9.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-02).
- Cormorant Global Healthcare Master Fund, LP: 1,919,971 shares (9.9% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-02).
- , the chief executive and a director: 157,316 shares (0.81% of shares outstanding) (Form 4, 2026-08-10).
- , the chief medical officer: 89,790 shares (0.46% of shares outstanding) (Form 4, 2026-03-04).
Shares outstanding: 19,341,293 as of 2026-08-04, from the company's latest SEC cover page.
How much has Corbus Pharmaceuticals Holdings, Inc. raised?
No fundraising or offering filing from Corbus Pharmaceuticals Holdings, Inc. is on file with us.
Keep reading
More on Corbus Pharmaceuticals Holdings, Inc. and the records around it.
Corbus Pharmaceuticals Holdings, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes May 2026
Companies that share a holder
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Precision BioSciences, Inc. (Nov 2026), Context Therapeutics Inc. (Jul 2026), Dianthus Therapeutics, Inc. /DE/ (May 2026)
- Aberdeen Group plc also filed stake reports on 12 other companies: Equillium, Inc. (Nov 2026), IMMUNIC, INC (Nov 2026), CODEXIS, INC. (Oct 2026)
- Cormorant Asset Management, LP also filed stake reports on 17 other companies: Adlai Nortye Ltd. (Aug 2026), BioAge Labs, Inc. (Aug 2026), Bright Minds Biosciences Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/corbus-pharmaceuticals